Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing therapies for rare genetic disorders and cardiometabolic diseases allowing for the development of up to seven programmes.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,920.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 24, 2023
Details:
The partnership will combine Life Edit's suite of proprietary gene editing technologies, including base editing, with Moderna's mRNA platform to advance in vivo gene editing mRNA-based therapies against a select set of therapeutic targets.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 22, 2023